Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease

Postgraduate Medical Journal

Volumn 85, Issue 1001, 2009, Pages 141-147

  Black, P N ^a   McDonald, C F ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BACTERIUM LYSATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CARBOCISTEINE; CILOMILAST; ERYTHROMYCIN; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INFLUENZA VACCINE; MOXIFLOXACIN; MUCOLYTIC AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; ROFLUMILAST; SALMETEROL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ANTIBIOTIC PROPHYLAXIS; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; INFLUENZA VACCINATION; LUNG RESECTION; NAUSEA; OXYGEN THERAPY; PNEUMONIA; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SMOKING CESSATION;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BACTERIA; BRONCHODILATOR AGENTS; EXPECTORANTS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; VACCINATION;

EID: 65349173726     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.072439     Document Type: Review

References (49)

1. British Thoracic Society. Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52:1-8.
2. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
3. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:358-64.
4. Seemungal TAR, Donaldson GC, Bhowmilk A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
5. National Heart, Lung and Blood Institute. Morbidity & mortality: 2007 chart book on cardiovascular, lung and blood diseases. http://www.nhbli.nih.gov/resources/docs/cht-book.htm (accessed 29 Jan 2009).
6. British Thoracic Society. Burden of lung disease report. 2nd edn. 2006. http://www.brit-thoracic.org.uk/Portals/O/Library/ BTS%20Publicationsburden-of-lung-disease2007.pdf (accessed 29 Jan 2009).
7. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S.
8. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease. The disease and its burden to society. Proc Am Thor Soc 2006;3:619-23.
9. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62.
10. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
11. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
12. Calverley PM, Boonswat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19.
13. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur RespirJ 2003;21:74-81.
14. Wedzicha JW, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
15. Aaron SD, Vandenheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007;146:545-55.
16. Aaron SD, Fergusson D, Marks GB, et al. Counting, analyzing and reporting exacerbations of COPD in randomized controlled trials. Thorax 2008;63:122-8.
17. Poole PJ, Black PN. Systematic review of mucolytics for prevention of exacerbations in chronic bronchitis. BMJ 2001;322:1271-1.
18. Decramer M, Rutten- van Molken M, Dekhuijzen PN, et al. Effects of N- acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552-60.
19. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD001287.
20. Zheng J-P, Kang J, Huang S-G, et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo- controlled study. Lancet 2008;371:2013-18.
21. Barnes PJ. Theophylline: a new perspective for an old drug. Am J Respir Crit Care Med 2003;167:813-18.
22. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized double-blind, parallel group, placebo-controlled study of low-dose. Slow release theophylline in the treatment of COPD for 1 year. Respirology 2006;11:603-10.
23. Rennard SI, Schacter N, Strek M, et al. Cilomilast for COPD. Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129:56-66.
24. Calverley PMA, Sanchez-Toril F, Mclvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61.
25. Black P, Staykova T, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003;1 :CD004105.
26. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
27. Seemungal TAR, Wilkinson TMA, Hurst JR, et al. Long term erythromycin therapy is associated with decreased COPD exacerbations. Am J Respir Crit Care Med 2008 [Epub ahead of print 21 August 2008].
28. Black PN. Antibiotics for the treatment of asthma. Curr Opin Pharmacol 2007;7:266-71.
29. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004;10:515-23.
30. Sethi S, Anzuetto A, Wilson R, et al. Placebo-controlled, double-blind trial of chronic intermittent "pulse" therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data. Eur Respir J 2006;28(Suppl 50):842s.
31. Arandjus C, Black PN, Poole PJ, et al. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis. Respir Med 2006;100: 1671-81.
32. Steurer-Stey C, Bachman LM, Steurer J, et al. Oral purified bacterial extracts in chronic bronchitis and COPD. Chest 2004;126:1645-55.
33. Collet JP, Shapiro S, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:1719-24.
34. Poole PJ, Chacko E, Wood-Baker RW, et al. lnfluenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;1:CD002733.
35. Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD. Current practice and future directions. Chest 2008;133:767-74.
36. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002;20:2166-73.
37. Granger R, Walters J, Poole PJ, et al. lnjectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;4:CD001390.
38. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348:1747-55.
39. Nichol KL, Baken L, Wuorenma K, et al. The health and economic benefits associated with pneumococcal vaccination of elderly patients with chronic lung disease. Arch Intern Med 1999;159:2437-12.
40. Cutts FT, Zaman SMA, Enwere G, et al. Efficacy of nine- valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005;365:1139-16.
41. Grijalva CG, Nuartu JP, Arbagast PG, et al. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time series analysis. Lancet 2007;369:1179-86.
42. Godtfredsen NS, Vestbo J, Osler M, et al. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002;57:967-72.
43. Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996;348:1115-19.
44. Griffiths TL, Burr ML, Campbell lA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation; a randomized controlled trial. Lancet 2000;355:362-8.
45. Man WDC, Polkey Ml, Donaldson N, et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ 2004;329:1209.
46. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalization in hypoxaemic chronic obstructive pulmonary disease? Eur Respir J 2002;20:38-42.
47. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;177:164-9.
48. Effing T, Monninkof EM, van der Valk PD, et al. Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD002990.
49. Bourbeau J, Julien M, Maltais F, et al. Reduction in hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003;163:585-91.